A new era for radiolabeled antibodies in cancer?

Radioimmunotherapy (RIT), a therapy targeted to tumor cells, is a modality that can currently deliver radiation to tumor cells at levels 3-50-times hi gher than to the normal tissue with the next highest dose. RIT appears prom ising for future cancer therapy. Clinical responses in patients with advanc ed cancer have frequently been achieved with RIT as a single agent. Extende d complete remissions and even increased survival have been achieved in lym phoma. Similar results in other cancers seem likely with RIT in combination therapy.